drugset / Trial / NCT06628206
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this clinical trial is to study the drug LPX-TI641 in patients with rheumatoid arthritis and psoriatic arthritis. We will compare the safety and tolerability of LPX-TI641 to placebo that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
Timeline
- Start
- 2024-12-15
- Primary completion
- 2025-12-15
- Completion
- 2026-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LPX-TI641 | Small molecule | 60 mg | Oral |
| Subject | LPX-TI641 | Small molecule | 120 mg | Oral |
| Subject | LPX-TI641 | Small molecule | 150 mg | Oral |